Pharmaceutical Price-Fixing Conspiracy

Overview

The pharmaceutical price-fixing conspiracy is not a theory — it is a documented, prosecuted, and in many cases adjudicated reality. Over the past three decades, multiple pharmaceutical companies have been caught engaging in illegal price-fixing, market allocation, and bid-rigging schemes that inflated the cost of prescription drugs for millions of patients, hospitals, insurance companies, and government health programs. These are not allegations from fringe activists but findings from Department of Justice criminal investigations, state attorney general lawsuits, congressional inquiries, and corporate guilty pleas.

The scope of confirmed pharmaceutical price manipulation spans several distinct but related schemes. The generic drug price-fixing cartel, uncovered beginning in 2014, involved more than thirty companies coordinating price increases on hundreds of generic medications and has been described by prosecutors as the largest criminal cartel case in American history. The insulin pricing scandal involved the three dominant manufacturers — Eli Lilly, Sanofi, and Novo Nordisk — raising prices in apparent lockstep over two decades, resulting in a more than tenfold increase in the cost of a drug essential for millions of diabetics. Individual cases like Martin Shkreli’s 5,455 percent overnight increase in the price of Daraprim illustrated the broader dynamics of pharmaceutical pricing power in a system with limited regulatory constraints.

What makes this topic relevant to the study of conspiracy theories is the gap between public awareness and the scale of the documented misconduct. For decades, allegations of pharmaceutical price coordination were dismissed as populist rhetoric or anti-corporate paranoia. The eventual confirmation of these schemes — through wiretaps, cooperating witnesses, guilty pleas, and documentary evidence — represents one of the clearest modern examples of a “conspiracy theory” that turned out to be substantially true.

Origins & History

Concerns about pharmaceutical pricing practices date back decades, but the modern era of confirmed price-fixing conspiracies begins in the 1990s and accelerates dramatically in the 2010s.

The pharmaceutical industry has long operated under conditions that facilitate anti-competitive behavior. The market for many drugs, particularly generics, is characterized by a small number of manufacturers, high barriers to entry, complex regulatory approval processes, and opaque pricing structures. Pharmacy benefit managers (PBMs) — intermediaries between drug manufacturers and insurance companies — add additional layers of complexity that obscure the relationship between manufacturing costs and consumer prices. These structural conditions create both the opportunity and the incentive for price coordination.

The generic drug price-fixing conspiracy was uncovered through a combination of whistleblower cooperation and federal investigation. In 2013, the Connecticut Attorney General’s office began receiving complaints from pharmacies about sudden, coordinated price increases on multiple generic drugs. Drugs that had been stable in price for years were suddenly increasing by hundreds or thousands of percent, often within days of each other across multiple manufacturers. The pattern was too consistent to be explained by market forces alone.

The investigation escalated to the federal level when the Department of Justice’s Antitrust Division became involved. A key breakthrough came when a sales executive at Heritage Pharmaceuticals, Jason Malek, agreed to cooperate with investigators. Malek provided detailed accounts of how competitors coordinated pricing through trade association meetings, industry dinners, golf outings, and direct communications. The picture that emerged was of an industry in which executives at competing companies regularly discussed and agreed upon pricing strategies for specific drugs, allocated customers and market shares, and coordinated the timing of price increases.

Simultaneously, public attention focused on the insulin market, where three companies — Eli Lilly, Sanofi, and Novo Nordisk — controlled approximately 90 percent of global insulin supply. Between 2002 and 2019, the list price of insulin products increased by more than 1,000 percent. The three companies raised prices in what appeared to be coordinated fashion, with one company’s price increase typically followed within days or weeks by matching increases from the other two. For the estimated 7.4 million Americans who depend on insulin, these increases were not abstract — they forced patients to ration doses, skip meals, and in some documented cases, die from inability to afford their medication.

The Shkreli case, while not technically a price-fixing conspiracy (it involved a single company exercising monopoly pricing power), crystallized public outrage about pharmaceutical pricing practices. When Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750 per tablet in September 2015, the story received enormous media coverage and made Shkreli one of the most publicly reviled figures in American business. Congressional hearings followed, though they produced limited legislative action.

Key Claims

The confirmed and alleged pharmaceutical price-fixing schemes share several common characteristics:

• Direct competitor coordination: Executives at competing pharmaceutical companies communicated directly to set prices, allocate markets, and coordinate the timing of price increases, in violation of federal antitrust law.

• Industry social events as cover: Price coordination frequently occurred at trade association conferences, industry dinners, and social events where competitors could meet without formal records. The generic drug cartel used events organized by industry groups as opportunities for illegal discussions.

• Hundreds of drugs affected: The generic drug price-fixing scheme was not limited to a few products. Federal and state investigations identified coordinated price increases on more than 300 generic drugs, affecting virtually every therapeutic category.

• Parallel pricing in insulin: The three major insulin manufacturers raised prices in apparent lockstep over nearly two decades, with price movements that were difficult to explain by independent market forces. Each company’s price increase was typically matched by competitors within a short timeframe.

• Exploitation of regulatory barriers: Companies exploited the FDA approval process, which can take years and cost millions, as a barrier to new market entrants who might offer competing products at lower prices. In some cases, companies engaged in strategies specifically designed to delay or block generic competitors.

• Patient harm and deaths: The price increases resulting from these schemes had direct consequences for patient health, including rationing of medications, skipped doses, medical bankruptcies, and in the case of insulin, documented deaths of patients unable to afford their prescriptions.

• PBM complicity: Critics allege that pharmacy benefit managers, which negotiate drug prices on behalf of insurance companies, benefited from higher list prices through larger rebates and had financial incentives not to challenge manufacturer pricing practices.

Evidence

The evidence of pharmaceutical price-fixing is extensive and comes from official legal proceedings.

Generic drug cartel — DOJ prosecution: Beginning in 2016, the Department of Justice Antitrust Division brought criminal charges against more than 30 generic drug companies and dozens of individual executives. Heritage Pharmaceuticals was the first company to plead guilty, in 2016, to conspiring to fix prices and allocate customers for the generic drugs doxycycline and glyburide. Subsequent indictments named executives at Teva Pharmaceutical Industries (the world’s largest generic drug manufacturer), Mylan, Sandoz, and numerous other companies.

Cooperating witness testimony: Multiple pharmaceutical executives who cooperated with federal investigators provided detailed testimony about how price-fixing worked in practice. Jason Malek and Jeffrey Glazer of Heritage Pharmaceuticals described a culture in which competitor coordination was routine and expected. Communications obtained through wiretaps and document subpoenas corroborated their accounts.

State attorney general litigation: In 2019, Connecticut Attorney General William Tong filed a lawsuit naming 20 generic drug manufacturers and citing evidence from more than 500,000 communications — emails, text messages, and phone records — demonstrating coordinated pricing activity. The complaint, which ran to nearly 500 pages, provided granular detail of how executives at competing companies agreed on specific price points for specific drugs.

Insulin pricing data: Public pricing databases document the parallel price increases by Eli Lilly, Sanofi, and Novo Nordisk. The list price of Humalog (Eli Lilly’s insulin lispro product) increased from approximately $21 per vial in 1996 to over $330 per vial by 2019. Novolog (Novo Nordisk) and Lantus (Sanofi) showed similar trajectories, with price changes often occurring within days of competitor moves.

Congressional investigations: Multiple congressional hearings examined pharmaceutical pricing practices. A 2019 Senate Finance Committee investigation into insulin pricing obtained internal company documents showing that manufacturers were aware of the competitive dynamics of their pricing decisions and monitored competitor pricing closely.

Shkreli case documentation: While Shkreli was ultimately convicted of securities fraud in 2017 (sentenced to seven years, later reduced), the Daraprim pricing episode was extensively documented through corporate communications, internal memos, and Shkreli’s own public statements, including social media posts in which he expressed indifference to patient impact.

Debunking / Verification

This conspiracy has a “confirmed” status because the core claims have been proven through criminal prosecutions, guilty pleas, and documentary evidence. However, some nuances deserve attention.

What is conclusively confirmed: Generic drug manufacturers engaged in criminal price-fixing conspiracies affecting hundreds of drugs. Heritage Pharmaceuticals and other companies pleaded guilty to federal charges. Dozens of executives were indicted. The existence of a coordinated generic drug cartel is not disputed.

What is strongly supported but not fully adjudicated: The insulin pricing allegations have produced lawsuits and settlements but, as of early 2026, have not resulted in criminal convictions for price-fixing. The three major insulin manufacturers have argued that their pricing decisions were made independently and that parallel pricing reflects rational market behavior rather than illegal coordination. Critics note that the pattern of nearly simultaneous price increases over two decades strains this explanation. The manufacturers’ decision in 2023-2024 to announce major price reductions — Eli Lilly capping insulin costs at $35 per month — was characterized by the companies as voluntary and by critics as an acknowledgment of indefensible pricing practices.

Industry defense: The pharmaceutical industry has argued that drug pricing reflects the cost of research and development, regulatory compliance, and the risk of clinical trial failures. Industry groups contend that focusing on list prices distorts the picture because negotiated discounts, rebates, and insurance coverage reduce actual out-of-pocket costs for many patients. Critics counter that the R&D argument does not apply to generic drugs (which require no original research) or to insulin (a century-old medication with well-established manufacturing processes) and that the rebate system primarily benefits intermediaries rather than patients.

Regulatory and legislative response: The Inflation Reduction Act of 2022 introduced provisions allowing Medicare to negotiate prices for certain high-cost drugs, representing the first significant federal legislative response to pharmaceutical pricing practices. Multiple states have enacted insulin price caps. These policy responses implicitly acknowledge the failure of market forces to constrain pharmaceutical pricing.

Cultural Impact

Pharmaceutical price-fixing has become one of the most politically potent corporate misconduct issues of the 21st century, reshaping public discourse about healthcare, corporate power, and regulatory failure.

Martin Shkreli became a cultural symbol disproportionate to his actual market impact. Dubbed “Pharma Bro” by the media, his unapologetic public persona — including smirking during congressional testimony and purchasing the sole copy of a Wu-Tang Clan album for $2 million — made him an avatar of perceived corporate sociopathy. His story was covered extensively in documentaries, podcasts, and news features, and his name became shorthand for pharmaceutical industry excess.

The insulin crisis produced deeply personal public narratives. Stories of diabetic patients dying after rationing insulin due to cost — including the widely reported case of Alec Smith, a 26-year-old Minnesota man who died in 2017 after aging out of his parents’ insurance and being unable to afford his medication — transformed the insulin pricing debate from an abstract policy discussion into a visceral human rights issue. The advocacy movement that emerged, led by patients and families, drove legislative action at state and federal levels.

The generic drug cartel case, despite involving larger dollar amounts and affecting more patients than the Shkreli episode, received comparatively less public attention — in part because the mechanics of generic drug pricing are less intuitive than a single dramatic price increase. However, the case has had significant impact within antitrust law and enforcement, establishing precedents for the investigation and prosecution of industry-wide pricing conspiracies.

Pharmaceutical price-fixing has also become a bipartisan political issue in an era of intense polarization. Politicians from across the ideological spectrum have criticized pharmaceutical pricing practices, though they differ on proposed solutions. This bipartisan consensus reflects the breadth of public concern — prescription drug costs affect voters regardless of political affiliation.

Key Figures

Martin Shkreli — Former CEO of Turing Pharmaceuticals who raised the price of Daraprim by 5,455 percent in 2015. Convicted of securities fraud in 2017. Became the public face of pharmaceutical pricing excess despite his relatively minor role in the broader industry.

Heather Bresch — CEO of Mylan who oversaw a 461 percent price increase in the EpiPen from 2007 to 2016. Faced congressional scrutiny and public backlash. Mylan was also named in the generic drug price-fixing investigation.

Jason Malek — Former Heritage Pharmaceuticals executive who became a key cooperating witness in the DOJ’s generic drug cartel investigation, providing detailed testimony about price-fixing practices.

William Tong — Connecticut Attorney General who led the most comprehensive state-level prosecution of generic drug price-fixing, filing a lawsuit in 2019 based on evidence from over 500,000 communications.

Makan Delrahim and Richard Powers — DOJ Antitrust Division officials who oversaw the federal criminal prosecution of the generic drug cartel.

Alec Smith — A 26-year-old Type 1 diabetic from Minnesota who died in 2017 after rationing insulin due to cost. His death became a catalyst for insulin pricing reform advocacy.

Senator Chuck Grassley and Senator Ron Wyden — Bipartisan Senate Finance Committee leaders who conducted congressional investigations into insulin pricing and broader pharmaceutical pricing practices.

Timeline

• 1990s — Early instances of pharmaceutical price-fixing investigations and settlements, primarily in the vitamin and chemical sectors.
• 2002–2019 — Insulin list prices increase by over 1,000 percent across all three major manufacturers, with price increases frequently occurring in parallel.
• 2013 — Connecticut Attorney General’s office begins receiving complaints about coordinated generic drug price spikes.
• 2014 — FBI and DOJ Antitrust Division begin criminal investigation into generic drug price-fixing.
• September 2015 — Martin Shkreli’s Turing Pharmaceuticals raises Daraprim price from $13.50 to $750 per tablet.
• 2016 — Heritage Pharmaceuticals pleads guilty to federal price-fixing charges, becoming the first company convicted in the generic drug cartel case.
• 2016 — Mylan faces congressional scrutiny over EpiPen pricing. CEO Heather Bresch testifies before Congress.
• 2017 — Martin Shkreli convicted of securities fraud. Alec Smith dies after rationing insulin.
• May 2019 — DOJ indicts former Teva executive for price-fixing involving more than 100 generic drugs.
• 2019 — Connecticut AG William Tong files comprehensive price-fixing lawsuit against 20 generic drug manufacturers.
• 2020 — Teva Pharmaceutical Industries indicted on federal price-fixing charges involving hundreds of generic drugs.
• 2020–2021 — Multiple state attorneys general file lawsuits against insulin manufacturers alleging coordinated pricing.
• 2022 — Inflation Reduction Act passes, allowing Medicare to negotiate prices for certain drugs and capping insulin copays for Medicare beneficiaries at $35.
• 2023 — Eli Lilly announces cap of $35 per month for insulin. Sanofi and Novo Nordisk follow with similar price reductions.
• 2024–2026 — Generic drug cartel prosecutions continue. Additional guilty pleas and settlements. Insulin pricing litigation proceeds in federal and state courts.

Sources & Further Reading

• United States Department of Justice, Antitrust Division. “Generic Pharmaceuticals Price Fixing Investigation.” Press releases and case documents, 2016–present.
• Eban, Katherine. Bottle of Lies: The Inside Story of the Generic Drug Boom. Ecco/HarperCollins, 2019.
• State of Connecticut v. Teva Pharmaceuticals USA et al. Superior Court of Connecticut, filed 2019.
• Senate Finance Committee. “Insulin: Examining the Factors Driving the Rising Cost of a Century-Old Drug.” Hearing and report, 2019.
• House Committee on Oversight and Reform. “A Painful Pill to Swallow: U.S. vs. International Prescription Drug Prices.” Report, 2019.
• Rowland, Christopher. “Insulin’s High Cost: Millions of Diabetics Face a Growing Crisis.” Washington Post, investigative series, 2019.
• Kolata, Gina. “The Cost of Insulin: A History.” New York Times, 2019.
• Dey, Soma. “The Generic Drug Cartel: How Drug Companies Conspired to Keep Prices High.” Bloomberg Businessweek, 2018.
• Zaitchik, Alexander. Owning the Sun: A People’s History of Monopoly Medicine, from Aspirin to COVID-19 Vaccines. Counterpoint Press, 2022.

Related Theories

• Big Pharma Conspiracy — The broader set of claims about pharmaceutical industry misconduct, influence, and prioritization of profits over patient welfare.
• Opioid Crisis Pharma Conspiracy — The confirmed role of pharmaceutical companies, particularly Purdue Pharma, in fueling the opioid addiction epidemic through deceptive marketing.
• Insulin Price-Fixing Conspiracy — A deeper examination of coordinated pricing practices among the three dominant insulin manufacturers.
• Drug Patent Evergreening Conspiracy — Strategies used by pharmaceutical companies to extend monopoly protection on drugs beyond the original patent period.